45 over 100 million varieties dominate the Chinese medicine market! 5 exclusive injections killed...

Pharmaceutical Network February 20, before the Spring Festival, "on the promotion of drug centralized band procurement normalized institutionalization of the views" issued, which will clearly explore the adaptation or functional treatment of similar different generic drugs combined to carry out centralized band procurement, this is obviously for traditional Chinese medicine and biological products collection procurement principles, it seems that traditional Chinese medicine difficult to standardize the problem will be solved through this combination.
as early as the second half of 2020, Zhejiang Jinhua, Qinghai, Liaoning, Henan and other provinces and cities launched the chinese medicine belt procurement pilot, for the Chinese medicine national procurement experience.
also made it clear at the State Council's policy briefing that "the inclusion of Chinese medicine in the collection is an institutional requirement, and the inclusion in the collection is beyond doubt".
chinese medicine will become the "pioneers" of the collection? Let's guess.
45 over 100 million varieties spread across 14 sub-categories, tumors, cerebrovascular, cardiovascular heat map 1:2020Q1-Q3 sales of more than 100 million sub-categories of Chinese medicine species distribution Source: Minernet key city public hospitals The scope of drug collection coverage is clearly defined in the Opinions of the Terminal Competition Pattern: In accordance with the principle of basic and clinical protection, the focus is on the inclusion of drugs in the list of basic medical insurance drugs with large quantities and high procurement amounts into the scope of procurement, and gradually covers all kinds of drugs that are clinically necessary and reliable for domestic market, so that they should be harvested.
the impact of the epidemic in 2020, reducing the frequency of patient visits to medical institutions, Milnet data show that in the first three quarters of 2020, key urban public hospitals end chemical drugs, Chinese medicine sales have declined, a decline of more than 10%.
in this grim situation, there are still 45 medium-old drug species sales of more than 100 million yuan, the ability to resist pressure is really strong.
These 45 varieties are distributed among 14 sub-categories, of which the largest proportion are cancer disease medication (10 over 100 million varieties), cerebrovascular disease drug use (9 billion varieties), cardiovascular disease drug use (9 over 100 million varieties).
10 more than 100 million varieties of cancer disease drug use are more affected by the epidemic, in addition to the positive growth of West Yellow, the remaining 9 varieties in the first three quarters of 2020 have seen a decline in sales trend; The growth rate was around 7%, apricots jumped 65%, sales of the remaining 7 varieties declined, and among the 9 varieties of cardiovascular disease medication, Shu Hening surged 42%, ginseng heart growth increased 4.5%, and sales of the remaining 7 varieties declined.
exclusive variety escape the collection? Health insurance negotiations have been sold in advance has been carried out five rounds of four batches of chemical drugs centralized procurement, from the selection of varieties are not exclusive, but can not be ignored is that the health care negotiations are in fact the national level for "lower drug prices, quality assurance" another set of big tricks.
2020 version of the National Health Insurance Directory will be officially implemented on March 1, 2021, 119 successful drug negotiations, of which 40 (30 are exclusive), Minenet data show that the lowest 2020 list price / winning bid compared to the 2020 health insurance price, 30 exclusive Chinese medicine prices fell by an average of more than 25%, this move has also been analyzed as another method of collection. Table
1:22 more than 100 million exclusive varieties of the situation (unit: billion yuan) Source: MiNet key city public hospital terminal competition pattern Minet data show that in the first three quarters of 2020 in key cities public hospital terminal sales of more than 100 million varieties of 22 for exclusive, in addition to Hiroshi pharmaceutical sodium chloride injection, the rest have been included in the 2020 version of the national health insurance directory.
sodium chloride injection is currently In Yunnan Province, Henan Province and other 9 provinces of the health insurance supplement catalog class B varieties, although the future will gradually clear the provincial supplement catalog, but earlier the network of the National Health Insurance Bureau developed the provincial volume procurement of 500 varieties of sodium chloride injection also appeared in the figure, the product will eventually be included in the national harvest? 2020 version of the National Health Insurance Directory adjustment for the first time set up a catalog drug price reduction negotiations, for the high cost, the fund occupied more exclusive drugs to further reduce the price, of which Danhong injection, injection with dansan polyphenols, Kangai injection, Conlet injection has earlier entered the 2009 version , 2017 and 2019 editions of the National Health Insurance Directory, which will remain in the National Health Insurance Directory until 2020 after negotiations: the standard of payment for the medical insurance of Dan Hong injection is 5.05 yuan (2 ml/branch), 17.32 yuan (10ml) (branch), 29.44 yuan (20ml/branch), medical insurance payment standard for injection of ginseng polyphenols is 31.69 yuan (50mg/bottle), 53.88 yuan (100mg/bottle), 91. 60 yuan (200mg/bottle), Kangai injection of medical insurance payment standard is 11.73 yuan (5ml/branch), 19.94 yuan (10ml/branch), 33.9 yuan (20ml/branch) The standard payment for Constand injections is 136 yuan (100ml: 10g/branch).
And blood must net injection, sputum heat capsules from the 2019 negotiations after the success of the national health insurance, is now the 2020 version of the national health insurance catalog negotiations varieties, the two exclusive products of the health insurance payment standard is 22.08 yuan (10ml/ branch), 4.3 yuan (0.4g / grain).
In June 2020, Jinhua City's second batch of drug belt procurement includes the collection of Chinese medicine, including pain relief paste, Lianhua Qing plague capsule, Conlet injection, Kangai injection, Danhong injection, cerebral heart pass capsule, heart-stabilizing particles, heart-to-heart capsules, ginseng In June of the same year, Qinghai Province's first batch of volume-purchased drugs catalog also has Magpie Ping injection, renal kang injection, injection with dansan polyphenols, sputum hydrochloride injection figure, these heavy exclusive varieties market attention is very high, will be targeted by the state, we will continue to observe.
"non-exclusive" crisis, blood plug through, compound Dansan, anti-cancer flat ... Competitive table 2:23 more than 100 million non-exclusive varieties of the situation (unit: billion yuan) Source: Minet key city public hospital terminal competition pattern of cerebrovascular disease drugs in the hundreds of millions of non-exclusive varieties involving thrombosis, blood plug, wake-up, ginseng and dansanchuan, which blood plug-in involved 2 injection products and 7 internal service products, in addition to blood plug-through foam tablets have entered the national health insurance products.
blood plug-through particles into Jinhua City, the second batch of drug belt procurement list, and injections, tablets, capsules, softgels, dispersion tablets and other dosage forms have also been included in Qinghai Province's first batch of volume procurement drug catalog, with the experience provided by the provincial collection, blood plug-through this large variety of Chinese medicine into the national collection of the probability is very great.
The non-exclusive varieties of cardiovascular disease drugs involving Ginkgo biloba extract, Shu henin, compound dansin, serum yellow pigment and large red landscape days, of which compound Dansan involved 5 products are served internally and are included in the national health insurance catalogue, Ginkgo biloba extract involving 1 injection and Ginkgo biloba tablets, Ginkgo biloba pills and other 9 endo-service products are included in the national health insurance catalogue.
Complex Dansan pills, compound Dansan tablets and Ginkgo leaf tablets have been included in Jinhua City's second batch of drug belt procurement, so it seems that these two large varieties of internal service products by the national collection of the probability is relatively high.
The non-exclusive varieties of more than 100 million drugs used in cancer diseases involve huayusin, crow bile oil, anti-cancer flat (clearing rattan), ginseng fuzheng, small gold and west yellow, of which anti-cancer flat (clearing rattan) involves 1 injection product and 5 inner Service products, customs rattan injection (anti-cancer flat injection), customs clearance rattan tablets (anti-cancer flat tablets), anti-cancer flat oral solution, anti-cancer flat capsules for the national health insurance catalog varieties, the current variety has not been included in the provincial collection, will become a national collection of dark horse? We'll see.
at this stage, the medical insurance negotiations and national collection has become an effective combination of "lower drug prices and quality assurance" at the national level, which not only brings practical benefits to patients, but also promotes the process of replacing raw drugs with high-end generic drugs, so that China's drug market has entered a new stage.
February 9, a notice on a number of policy measures to accelerate the development of Chinese medicine characteristics was issued to the outside world, with the aim of erring better exerting the characteristics and advantages of Chinese medicine and promoting the complementary and coordinated development of Chinese and Western medicine.
predictably, 2021 will be an important time for the Chinese medicine market to change.
The collection of Chinese medicine is imminent, but the industry believes that there are still several difficulties: Chinese medicine has not yet worked out a unified standard for drug collection, how to solve the problem of "consistent evaluation" of similar chemical drugs to be further discussed; "Label" products, in the collection will become the enterprise's "plus points" is still unknown, Chinese medicine is one of the Chinese characteristics, into the collection can undoubtedly increase the market volume, but after the "price war" will eliminate the determination of Chinese medicine enterprises to invest in research and development, has also become a hot topic in the industry.
source: Minet database